LPL Financial’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

LPL Financial’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-19,024	Closed	-$79.9K	–	4759
2023 Q1	$79.9K	Hold	19,024	–	–	﹤0.01%	4246
2022 Q4	$114K	Sell	19,024 -13,000	-41%	-$71K	﹤0.01%	4136
2022 Q3	$186K	Sell	32,024 -1,000	-3%	-$6.23K	﹤0.01%	3963
2022 Q2	$197K	Sell	33,024 -14,200	-30%	-$72.7K	﹤0.01%	3962
2022 Q1	$221K	Hold	47,224	–	–	﹤0.01%	3786
2021 Q4	$117K	Buy	+47,224	New	+$116K	﹤0.01%	4115
2019 Q2	–	Sell	-10,500	Closed	-$10K	–	3401
2019 Q1	$10K	Buy	+10,500	New	+$11.1K	﹤0.01%	3171
2016 Q1	–	Sell	-1,000	Closed	-$13K	–	3307
2015 Q4	$13K	Buy	+1,000	New	+$13.3K	﹤0.01%	3129

Other funds holding CTIC

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

LPL Financial's CTIC Position: Q2 2023 in Review

LPL Financial sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 19,024 shares — an estimated $79.9K sold.

LPL Financial first reported a position in CTIC in Q4 2015 and held it in 8 quarters. The position peaked at $221K in Q1 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

LPL Financial reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
LPL Financial sold 19,024 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $79.9K.
LPL Financial first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2015 and held it in 8 quarters.
LPL Financial's CTI BioPharma Corp. (DE) Common Stock position peaked at $221K in Q1 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on LPL Financial's 13F filing for Q2 2023, filed 31 Jul 2023.